drugset
drugset / Trial / NCT04353479

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

NCT04353479 ↗

Phase 2 Unknown 29 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single arm, phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with DNA methyltransferase inhibitor decitabine in elderly patients with relapse and refractory acute myeloid leukemia.

Timeline

Start
2020-04-25
Primary completion
2020-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody — —
Subject Decitabine Small molecule — —

Indications

acute myeloid leukemia